Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Enterprise Value for 5 consecutive years, with -$22.3 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 412.81% to -$22.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$22.3 million, a 412.81% decrease, with the full-year FY2025 number at -$14.3 million, changed N/A from a year prior.
- Enterprise Value was -$22.3 million for Q4 2025 at Neuphoria Therapeutics, down from -$13.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4.3 million in Q4 2024 to a low of -$24.0 million in Q2 2022.
- A 4-year average of -$14.5 million and a median of -$14.0 million in 2025 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 49.26% in 2023, then tumbled 412.81% in 2025.
- Neuphoria Therapeutics' Enterprise Value stood at -$24.0 million in 2022, then soared by 49.26% to -$12.2 million in 2023, then soared by 64.38% to -$4.3 million in 2024, then crashed by 412.81% to -$22.3 million in 2025.
- Per Business Quant, the three most recent readings for NEUP's Enterprise Value are -$22.3 million (Q4 2025), -$13.7 million (Q3 2025), and -$14.3 million (Q2 2025).